title: Application of kinetic-based computer modelling to evaluate the efficacy of HI 6 in percutaneous VX poisoning.
abstract: The rife use of organophosphorus compounds (OP) as pesticides and the exertion of highly toxic OP-type chemical warfare agents (nerve agents) during military conflicts and terrorist attacks in the past emphasize the necessity of the development of effective therapeutic countermeasures. Presently, standard treatment of poisoning by OP includes administration of atropine as an antimuscarinic agent and of oximes, e.g. obidoxime or pralidoxime, as reactivators of OP-inhibited acetylcholinesterase (AChE), but is considered to be rather ineffective with certain nerve agents. The evaluation of new oximes as antidotes is only possible by implementation of animal experiments for ethical reasons and therefore complicated by a limited extrapolation of animal data to humans due to marked species differences. A computer simulation based on combination of AChE kinetic data (inhibition, reactivation, aging) with OP toxicokinetics and oxime pharmacokinetics allows the calculation of AChE activities at different scenarios and may facilitate to define effective oxime concentrations and to optimize oxime dosage in OP poisoning. On the base of species-specific kinetic data this model was used to calculate AChE activities in humans and pigs after percutaneous exposure to 5 x LD50 VX and treatment with HI 6. Due to marked species differences between human and pig AChE the HI 6 dose that is necessary to cause a comparable reactivation of VX-inhibited pig AChE is conspicuously higher. Hence, designing animal experiments with the aid of computer modeling may reduce the number of animal experiments and allow a more reliable extrapolation of animal data to humans.
authors.affiliation: Bundeswehr Institute of Pharmacology and Toxicology, Neuherbergstrasse 11, 80937 Munich, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Aurbek
authors.forename: H
authors.initials: H
authors.lastname: Thiermann
authors.forename: L
authors.initials: L
authors.lastname: Szinicz
authors.forename: P
authors.initials: P
authors.lastname: Eyer
authors.forename: F
authors.initials: F
authors.lastname: Worek
mesh_terms: D000279:Administration, Cutaneous; D000465:Algorithms; D000818:Animals; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000506:poisoning*; D002801:Cholinesterase Reactivators / Q000627:therapeutic use*; D003198:Computer Simulation; D006801:Humans; D007700:Kinetics; D007928:Lethal Dose 50; D009946:Organothiophosphorus Compounds / Q000008:administration & dosage / Q000506:poisoning*; D010091:Oximes; D011726:Pyridinium Compounds / Q000627:therapeutic use*; D013045:Species Specificity; D013552:Swine
chemical_list: D002800:Cholinesterase Inhibitors; D002801:Cholinesterase Reactivators; D009946:Organothiophosphorus Compounds; D010091:Oximes; D011726:Pyridinium Compounds; C009680:VX-agent; C022870:asoxime chloride